- Home
- ARBK vs LSTA Comparison
ARBK vs LSTA Comparison
Compare ARBK & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBK
- LSTA
- Stock Information
- Founded
- ARBK 2017
- LSTA 1980
- Country
- ARBK United Kingdom
- LSTA United States
- Employees
- ARBK N/A
- LSTA N/A
- Industry
- ARBK Finance: Consumer Services
- LSTA Misc Health and Biotechnology Services
- Sector
- ARBK Finance
- LSTA Health Care
- Exchange
- ARBK Nasdaq
- LSTA Nasdaq
- Market Cap
- ARBK 25.8M
- LSTA 20.0M
- IPO Year
- ARBK 2021
- LSTA N/A
- Fundamental
- Price
- ARBK $0.40
- LSTA $2.32
- Analyst Decision
- ARBK Hold
- LSTA Strong Buy
- Analyst Count
- ARBK 2
- LSTA 1
- Target Price
- ARBK $1.45
- LSTA $15.00
- AVG Volume (30 Days)
- ARBK 4.1M
- LSTA 17.8K
- Earning Date
- ARBK 04-24-2025
- LSTA 05-08-2025
- Dividend Yield
- ARBK N/A
- LSTA N/A
- EPS Growth
- ARBK N/A
- LSTA N/A
- EPS
- ARBK N/A
- LSTA N/A
- Revenue
- ARBK $52,868,000.00
- LSTA $1,000,000.00
- Revenue This Year
- ARBK N/A
- LSTA N/A
- Revenue Next Year
- ARBK $175.58
- LSTA N/A
- P/E Ratio
- ARBK N/A
- LSTA N/A
- Revenue Growth
- ARBK 18.91
- LSTA N/A
- 52 Week Low
- ARBK $0.30
- LSTA $2.05
- 52 Week High
- ARBK $2.48
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- ARBK 42.95
- LSTA 42.12
- Support Level
- ARBK $0.36
- LSTA $2.07
- Resistance Level
- ARBK $0.43
- LSTA $2.62
- Average True Range (ATR)
- ARBK 0.08
- LSTA 0.21
- MACD
- ARBK 0.01
- LSTA 0.01
- Stochastic Oscillator
- ARBK 28.03
- LSTA 47.37
Stock Price Comparison Chart: ARBK vs LSTA
■ ARBK
■ LSTA
About ARBK Argo Blockchain plc
Argo Blockchain PLC is a data center business that provides a powerful and efficient platform for cryptocurrency mining operations. The company has operations in strategic locations in North America.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
Share on Social Networks:
0